Vericel Corporation is a biotechnology company that develops and manufactures advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets. The company markets two FDA-approved autologous cell therapy products and one FDA-approved specialty biologic product in the United States. Its primary product, MACI, is an autologous cellularized scaffold indicated for the repair of full-thickness cartilage defects in the knee, with an expanded indication for arthroscopic delivery via MACI Arthro instruments. Epicel is a permanent skin replacement indicated for the treatment of deep-dermal or full-thickness burns. Vericel also holds exclusive North American rights to NexoBrid, a topically administered biological orphan product for eschar removal in thermal burns, licensed from MediWound Ltd. The company manufactures MACI and Epicel at facilities in Massachusetts and sources NexoBrid from MediWound, with manufacturing primarily located in Israel. Vericel previously marketed Carticel, the first FDA-approved autologous cartilage repair product, until 2017. The company serves orthopedic surgeons and burn centers, focusing on regenerative medicine solutions for cartilage repair and skin regeneration.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage vcel.com
Sector Healthcare IR page investors.vcel.com/sec-filings
Tags
cell therapy, sports medicine, burn care, cartilage repair, skin regeneration, autologous chondrocyte implantation, eschar removal, tissue engineering, specialty biologics, MACI, Epicel, NexoBrid, MACI Arthro, Carticel, MediWound, Matricel, ACI-Maix
Press page —

Metrics

Valuation  
Market cap $ 2.947B
Market cap (USD) $ 2.947B
P/E 88.82
PEG —
P/BV 7.67
P/S 9.09
P/OCF 45.12
P/FCF 50.90
Dividend yield —
Turnover / mcap —
Returns  
ROE 5.1%
ROI 6.5%
ROIC 4.1%
Profit margin 6.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score 11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 276.259M 237.224M 197.516M 163.698M 153.075M 121.968M 117.85M 90.857M 63.924M 54.383M 51.168M 28.796M 19K 21K 18K — — — — — — — — — —
Net profit 16.518M 10.362M -3.182M -16.709M -7.471M 2.864M -9.665M -8.137M -17.286M -19.566M -16.34M -19.92M -15.622M -29.474M -19.668M — — — — — — — — — -9.39M
Free cash flow 24.748M -5.811M 15.298M 10.091M 21.125M 14.946M -9.799M -3.09M -14.693M -21.307M -15.773M -26.239M -19.983M -29.818M -25.523M — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 36.01 54.91 35.61 26.34 39.3 30.88 17.4 17.4 5.45 3 2.58 3.04 — — — — — — — — — — — — —
Price performance 12m -0.34 0.54 0.35 -0.33 0.27 0.77 -0 2.19 0.82 0.16 -0.15 — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 17.1M 18.3M 23.5M 32.2M 34.5M 37.4M 46.5M 58.4M 61.4M 84.6M
↳ YoY growth +56.5% +6.9% +28.4% +37.2% +7.3% +8.5% +24.3% +25.4% +5.2% +37.9%
↳ 5y CAGR +352.6% +265.5% +393.7% +31.5% +25.9% +17.0% +20.6% +20.0% +13.8% +19.7%
Borrowings, non-current (USD) 9.32M 16.9M — — — — — — — —
Lease liabilities (USD) — — 0.00 27.9M 53.3M 50.2M 47.6M 88M 99.5M 96.9M
Cash and deposits (USD) 23M 26.9M 18.3M 26.9M 33.6M 68.3M 51.1M 69.1M 74.5M 100M
Intangible assets (USD) 0.00 — — — — 0.00 7.5M 6.88M 6.25M 5.63M
Right-of-use assets (USD) — — 0.00 25.1M 50.1M 45.7M 41.5M 73.5M 70.1M 64.8M
Net debt (borrowings + leases - cash) (USD) — -9.97M — — — — — — — —
Cash flow detail
Operating cash flow (USD) -19.9M -13.2M -412,000 -7.18M 17.6M 29M 17.7M 35.3M 58.2M 51.9M
Purchases of property, plant and equipment (USD) -1.42M -1.51M -2.68M -2.62M -2.63M -7.92M -7.6M -20M -64M -27.2M
Purchases of intangible assets (USD) — — — — — 0.00 0.00 -7.5M 0.00 0.00
Change in receivables (cash effect) (USD) -6.17M -1.18M -5.18M -8.71M -2.34M -2.93M -9.1M -11.8M -3.02M -23.3M
Change in inventories (cash effect) (USD) -2.25M -657,000 235,000 -3.26M -2.54M -4.03M -2.61M 2.9M -4.29M -1.23M
Change in payables (cash effect) (USD) -1.08M -1.36M 899,000 -1.02M 33,000 1.49M 1.44M 3.05M -287,000 2.97M
Interest paid (cash effect) (USD) -226,000 -931,000 -2.23M 0.00 -6,000 -4,000 -109,000 -383,000 -399,000 -489,000
Income taxes paid (cash effect) (USD) 0.00 -100,000 0.00 0.00 -147,000 -379,000 0.00 -1.17M -628,000 -580,000
Share-based compensation (USD) 2.5M 2.68M 7.22M 13.2M 13.8M 34.3M 37.2M 32.3M 36.5M 38.8M
Operating cash flow before change in receivables (USD) -13.7M -12M 4.77M 1.53M 19.9M 32M 26.8M 47.1M 61.2M 75.2M
Free cash flow (OCF - PPE - intangibles) (USD) -21.3M -14.7M -3.09M -9.8M 14.9M 21.1M 10.1M 7.8M -5.81M 24.7M
Income detail
Research and development expense (USD) 15.3M 12.9M 13.6M 30.4M 13M 16.3M 19.9M 21M 24.8M 27.6M
↳ 5y CAGR -6.4% -13.0% -2.1% +7.4% -7.2% +1.3% +9.0% +9.1% -4.0% +16.2%
Total comprehensive income (USD) -19.6M -17.3M -8.18M -9.61M 2.86M -7.64M -17.5M -2.3M 10.5M 16.8M
Comprehensive income to owners (USD) -19.6M -17.3M -8.18M -9.61M 2.86M -7.64M -17.5M -2.3M 10.5M 16.8M
Reported Feb 25, 2020 Aug 6, 2018 May 7, 2019 Feb 25, 2020 Feb 24, 2022 Feb 29, 2024 Feb 29, 2024 Feb 29, 2024 Feb 27, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

25 Blue Sky Drive Burlington, MA 01803 Bull 5 Bear 0 Results

T 617 588-5555 F 617 588-5554

www.vcel.com

Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

Total Revenue Growth of 26% to $85.4 Million

Net Income Increased 179% to $14.2 Million

Adjusted EBITDA Margin of 30%

Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28%

Conference Call Today at 8:30am Eastern Time

BURLINGTON, Mass., November 5, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2026.

November 5, 2026 at 7:55 AM EST

PDF Version

**Total Revenue Growth of 26% to $85.4 MillionNet Income Increased 179% to $14.2 MillionAdjusted EBITDA Margin of 30%****Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28%**Conference Call Today at 8:30am Eastern Time

BURLINGTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Highlights

  • Total net revenue growth of 26% to $85.4 million

  • MACI® net revenue growth of 21% to $67.4 million

  • Burn Care net revenue growth of 52% to $18.0 million, with Epicel® revenue of $12.7 million and NexoBrid® revenue of $5.3 million

  • Gross margin of 73%

  • Net income increased 179% to $14.2 million, or $0.27 per diluted share

  • Non-GAAP adjusted EBITDA increased 48% to $25.2 million, or 30% of revenue

  • Operating cash flow of $17.7 million

  • Free cash flow of $15.7 million

  • $235.6 million in cash and investments, and no debt

Year-to-Date 2026 Financial Highlights

  • Total net revenue growth of 26% to $231.3 million

  • MACI net revenue growth of 22% to $189.3 million

  • Burn Care net revenue growth of 50% to $42.0 million

  • Adjusted EBITDA growth of 48% to $49.6 million

  • Operating cash flow of $50.3 million

  • Free cash flow of $45.1 million

Business Highlights and Updates

  • Record third quarter total revenue and MACI revenue, and the highest quarterly Burn Care revenue to date

  • MACI revenue growth of 20% or more for the sixth consecutive quarter

  • Highest Epicel quarterly revenue since launch, which increased 23% versus the prior year

  • Highest NexoBrid quarterly commercial revenue since launch, with 54% growth versus the prior year and 46% growth versus the prior quarter

  • Recognized $3.0 million of BARDA procurement revenue in the third quarter

  • Record third quarter MACI biopsies, implants and biopsy and implanting surgeons, with biopsy growth increasing each quarter this year compared to the prior year

  • Highest number of MACI Arthro cases in any quarter since launch in the third quarter

  • The Company remains on track for a potential MACI launch in the U.K. in 2027

  • Repurchased 220,744 shares of common stock for $8.8 million during the quarter, with $191.2 million of share repurchase authorization remaining as of September 30, 2026

“The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders,” said Nick Colangelo, President and CEO of Vericel. “Given our third quarter outperformance and the strong start to the fourth quarter for both commercial businesses, and particularly for MACI, we believe that the Company is very well-positioned for a strong close to 2026 and to sustain this momentum in 2027 and beyond.”

2026 Full-Year Financial Guidance

  • Raised total revenue guidance to $344 to $346 million, compared to $330 to $340 million previously

  • Raised MACI revenue guidance to $290 to $292 million, compared to $284 to $290 million previously

  • Raised Burn Care revenue guidance to $54 million, compared to $46 to $50 million previously

  • Raised adjusted EBITDA margin guidance to 28%, compared to 27% previously

  • Reaffirmed full-year gross margin of approximately 75%

Third Quarter 2026 Results Total net revenue for the quarter ended September 30, 2026 increased 26% to $85.4 million, compared to $67.5 million in the third quarter of 2025. Total net product revenue for the quarter included $67.4 million of MACI (autologous cultured chondrocytes on porcine collagen membrane) net revenue, $12.7 million of Epicel (cultured epidermal autografts) net revenue, $2.3 million of NexoBrid (anacaulase-bcdb) commercial net revenue and $3.0 million of NexoBrid BARDA procurement revenue, compared to $55.7 million of MACI net revenue, $10.4 million of Epicel net revenue, and $1.5 million of commercial NexoBrid net revenue, respectively, in the third quarter of 2025.

Gross profit for the quarter ended September 30, 2026 was $62.6 million, or 73% of net revenue, compared to $49.6 million, or 73% of net revenue, for the third quarter of 2025.

Total operating expenses for the quarter ended September 30, 2026 were $50.4 million, compared to $46.1 million for the same period in 2025. The increase in operating expenses was primarily due to increased headcount and related employee expenses, including the MACI sales force expansion, and an increase in marketing programs.

Net income for the quarter ended September 30, 2026 was $14.2 million, or $0.27 per diluted share, compared to $5.1 million, or $0.10 per diluted share, for the third quarter of 2025.

Non-GAAP adjusted EBITDA for the quarter ended September 30, 2026 was $25.2 million, or 30% of net revenue, compared to $17.0 million, or 25% of net revenue, for the third quarter of 2025. A table reconciling non-GAAP measures is included in this press release for reference.

Conference Call Information Today’s conference call will be available live at 8:30 a.m. Eastern Time. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the Vericel website. A replay of the webcast will be available until November 5, 2027.

To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connecting, please use passcode:787594.

About Vericel CorporationVericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. For more information, please visit www.vcel.com.

Epicel®, MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.

GAAP v. Non-GAAP Measures Vericel’s reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission (SEC). Vericel has provided in this release certain financial information that has not been prepared in accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted EBITDA, which includes adjustments for specific items that are generally not indicative of our core operations, and free cash flow described in this release, provide additional information that is useful to investors in understanding Vericel’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Vericel’s industry. However, the non-GAAP financial measures that Vericel uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.

Forward-Looking StatementsVericel cautions you that all statements other than statements of historical fact included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.

Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI, MACI Arthro, Epicel, and NexoBrid in the U.S. and in applicable markets outside the U.S., growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, the ability to sustain profitability, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the use of MACI to treat cartilage defects in the ankle, the timing and likelihood of obtaining marketing approval for MACI in the United Kingdom, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, including recent and future healthcare and drug pricing reform measures and private payor initiatives, surgeon adoption of MACI Arthro, physician and burn center adoption of NexoBrid, labor strikes, supply chain disruptions or other events or factors that might affect our ability to manufacture MACI or Epicel or affect MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to conflicts in the Middle East region involving Israel or those related to disruptions of land or sea transportation routes or distribution or shipping channels, uncertainties associated with the potential benefits of the Company’s agreement with BARDA for the procurement and development of NexoBrid and the availability of funding from BARDA under that agreement, negative impacts on the global economy and capital markets resulting from the conflicts in Ukraine and Iran, as well as other hostilities in the Middle East, changes in trade policies and regulations, including the potential for increases or changes in duties, current and potentially new tariffs or quotas, lingering effects of adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, changes in governmental monetary and fiscal policies, including, but not limited to, Federal Reserve policies in connection with continued inflationary pressures, the impact from future regulatory, judicial and legislative changes affecting our industry or the broader market, including those included in the One Big Beautiful Bill Act, and a U.S. government shutdown.

These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 26, 2026, Vericel’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 5, 2026, and in other filings with the SEC. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

**Investor Contact:**Eric Burns [email protected] +1 (734) 418-4411

| VERICEL CORPORATION |

| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |

| (in thousands, except per share amounts - unaudited) |

| |

| |

| | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Product sales, net | | $ | 85,371 | | | $ | 67,503 | | | $ | 231,253 | | | $ | 183,341 | |

| Total revenue | | | 85,371 | | | | 67,503 | | | | 231,253 | | | | 183,341 | |

| Cost of product sales | | | 22,761 | | | | 17,918 | | | | 62,975 | | | | 50,870 | |

| Gross profit | | | 62,610 | | | | 49,585 | | | | 168,278 | | | | 132,471 | |

| Research and development | | | 6,885 | | | | 6,318 | | | | 22,482 | | | | 20,310 | |

| Selling, general and administrative | | | 43,539 | | | | 39,817 | | | | 141,240 | | | | 123,532 | |

| Total operating expenses | | | 50,424 | | | | 46,135 | | | | 163,722 | | | | 143,842 | |

| Income (loss) from operations | | | 12,186 | | | | 3,450 | | | | 4,556 | | | | (11,371) | |

| Other income (expense): | | | | | | | | |

| Interest income | | | 2,152 | | | | 1,808 | | | | 5,957 | | | | 5,122 | |

| Interest expense | | | (160) | | | | (158) | | | | (480) | | | | (468) | |

| Other (expense) income | | | (17) | | | | (26) | | | | 32 | | | | (8) | |

| Total other income | | | 1,975 | | | | 1,624 | | | | 5,509 | | | | 4,646 | |

| Net income (loss) | | $ | 14,161 | | | $ | 5,074 | | | $ | 10,065 | | | $ | (6,725) | |

| Net income (loss) per common share: | | | | | | | | |

| Basic | | $ | 0.28 | | | $ | 0.10 | | | $ | 0.20 | | | $ | (0.13) | |

| Diluted | | $ | 0.27 | | | $ | 0.10 | | | $ | 0.19 | | | $ | (0.13) | |

| Weighted-average common shares outstanding: | | | | | | | | |

| Basic | | | 51,186 | | | | 50,489 | | | | 51,013 | | | | 50,256 | |

| Diluted | | | 52,962 | | | | 51,908 | | | | 52,459 | | | | 50,256 | |

| VERICEL CORPORATION |

| RECONCILIATION OF REPORTED NET INCOME (LOSS) (GAAP) |

| TO ADJUSTED EBITDA (NON-GAAP MEASURE) |

| (in thousands - unaudited) |

| |

| |

| | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Net income (loss) | | $ | 14,161 | | | $ | 5,074 | | | $ | 10,065 | | | $ | (6,725) | |

| Stock-based compensation expense | | | 7,823 | | | | 8,699 | | | | 28,200 | | | | 30,344 | |

| Depreciation and amortization | | | 3,627 | | | | 2,944 | | | | 10,514 | | | | 8,456 | |

| Net interest income | | | (1,992) | | | | (1,654) | | | | (5,485) | | | | (4,658) | |

| Pre-occupancy lease expense and tech transfer | | | 1,604 | | | | 1,933 | | | | 6,349 | | | | 6,180 | |

| Adjusted EBITDA (Non-GAAP) | | $ | 25,223 | | | $ | 16,996 | | | $ | 49,643 | | | $ | 33,597 | |

| VERICEL CORPORATION |

| RECONCILIATION OF FREE CASH FLOW (NON-GAAP MEASURE) |

| (in thousands - unaudited) |

| |

| |

| | | Three Months Ended September 30, | | Nine Months Ended September 30, |

| | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | |

| Net cash provided by operating activities | | $ | 17,723 | | | $ | 22,082 | | | $ | 50,297 | | | $ | 36,896 | |

| Capital expenditures | | | (2,042) | | | | (2,630) | | | | (5,231) | | | | (24,975) | |

| Free cash flow (Non-GAAP) | | $ | 15,681 | | | $ | 19,452 | | | $ | 45,066 | | | $ | 11,921 | |

| | | | | | | | | |

| Net cash used in investing activities | | $ | (2,708) | | | $ | (3,377) | | | $ | (9,729) | | | $ | (27,547) | |

| Net cash (used in) provided by financing activities | | $ | (6,880) | | | $ | 1,166 | | | $ | (7,167) | | | $ | 6,005 | |

| VERICEL CORPORATION |

| CONDENSED CONSOLIDATED BALANCE SHEETS |

| (in thousands - unaudited) |

| |

| |

| | | September 30, | | December 31, |

| | | | 2026 | | | 2025 |

| ASSETS | | | | |

| Current assets: | | | | |

| Cash and cash equivalents | | $ | 133,493 | | $ | 100,092 |

| Short-term investments | | | 36,775 | | | 37,407 |

| Accounts receivable (net of allowance for doubtful accounts of $23 and $13, respectively) | | | 81,798 | | | 84,634 |

| Inventory | | | 17,056 | | | 17,560 |

| Other current assets | | | 11,648 | | | 7,744 |

| Total current assets | | | 280,770 | | | 247,437 |

| Property and equipment, net | | | 105,079 | | | 108,397 |

| Intangible assets, net | | | 5,156 | | | 5,625 |

| Right-of-use assets | | | 60,590 | | | 64,774 |

| Long-term investments | | | 65,336 | | | 61,395 |

| Other long-term assets | | | 179 | | | 341 |

| Total assets | | $ | 517,110 | | $ | 487,969 |

| LIABILITIES AND SHAREHOLDERS’ EQUITY | | | | |

| Current liabilities: | | | | |

| Accounts payable | | $ | 19,958 | | $ | 15,828 |

| Accrued expenses | | | 20,391 | | | 19,236 |

| Current portion of operating lease liabilities | | | 14,254 | | | 13,969 |

| Other current liabilities | | | 116 | | | 116 |

| Total current liabilities | | | 54,719 | | | 49,149 |

| Operating lease liabilities | | | 76,319 | | | 82,284 |

| Other long-term liabilities | | | 1,900 | | | 1,896 |

| Total liabilities | | | 132,938 | | | 133,329 |

| Total shareholders’ equity | | | 384,172 | | | 354,640 |

| Total liabilities and shareholders’ equity | | $ | 517,110 | | $ | 487,969 |

NASDAQ: VCEL

| $54.62 | +2.84 (+5.48%) |

Day High: $54.64 Day Low: $50.76 Volume: 1,616,567

4:00 PM EST on Nov 6, 2026

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Presentation

Investor Presentation Title Slide

Company Presentation 4 MB

October 22, 2026 at 8:30 AM EDT

PDF Version

BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its third quarter 2026 financial results on Thursday, November 5, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until November 5, 2027.

To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connected, please use passcode: 787594.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com. Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.

Investor Contact:

Eric Burns [email protected] +1 (734) 418-4411

NASDAQ: VCEL

| $42.77 | +1.68 (+4.09%) |

Day High: $43.05 Day Low: $41.48 Volume: 232,678

2:17 PM EDT on Oct 29, 2026

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Company Presentation

Investor Presentation Title Slide

Company Presentation 4 MB

Prompts

Vericel Corporation (ticker VCEL), listed in United States.

Company History

Date Change Detail
Nov 24, 2014 Renamed AASTROM BIOSCIENCES INC → VERICEL CORP

ETFs Holding Vericel Corporation

ETF Weight in ETF Shares Market value As of
JSMD 1.03% 236,414 $ 10.866M Jul 31, 2026
JSML 0.96% 75,417 $ 3.466M Jul 31, 2026
LITL 0.78% 765 $ 44.278K Nov 17, 2026
FSEG 0.17% 216 $ 9,609.84 Jun 30, 2026
SMDX 0.16% 3,551 $ 204.111K Nov 17, 2026
RESM 0.07% 59 $ 2,624.91 Jun 30, 2026
DFAS 0.06% 361,314 $ 20.747M Nov 12, 2026
FESM 0.04% 51,440 $ 2.289M Jun 30, 2026
MSSM 0.01% 1,892 $ 75.491K Aug 31, 2026
DFAC 0.01% 151,110 $ 8.677M Nov 12, 2026
DCOR 0.01% 52,827 $ 3.033M Nov 12, 2026
DFAU 0.00% 11,146 $ 640.003K Nov 12, 2026
DFSU 0.00% 1,999 $ 114.783K Nov 12, 2026
DFUS 0.00% 15,381 $ 883.177K Nov 12, 2026
EBI 0.00% 13 $ 518.70 Aug 31, 2026
AVUS 0.00% 1,278 $ 73.459K Nov 16, 2026